Abstract
Hyperuricemia (HU) has been considered to be associated with adverse outcomes in CKD due to reduced glomerular filtration rate. Recently, some studies have suggested that HU is an independent risk factor for renal disease progression. However, whether uric acid-lowering therapy can retard the progression of CKD is unclear. The aim of our study is to assess the effect of treatment in the progression of chronic renal disease as well as the transition to chronic renal failure.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
